The glucagon pathway is suspected of being the target of BBR beyond the insulin pathway because abnormally elevated glucagon levels and increased hepatic glucagon sensitivity drive hepatic gluconeogenesis in type 2 diabetic patients [13]. This evidence concerns the gene INS and type 2 diabetes mellitus.